Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. - Le Saux O; Ardin M; Berthet J; Barrin S; Bourhis M; Cinier J; Lounici Y; Treilleux I; Just PA; Bataillon G; Savoye AM; Mouret-Reynier MA; et al. (Nature communications, 2024)